GSA Capital Partners LLP Reduces Stock Position in SELLAS Life Sciences Group, Inc. $SLS

GSA Capital Partners LLP lessened its position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 33.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 345,052 shares of the company’s stock after selling 173,943 shares during the quarter. GSA Capital Partners LLP owned 0.24% of SELLAS Life Sciences Group worth $1,301,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Grange Capital LLC lifted its holdings in shares of SELLAS Life Sciences Group by 18.5% in the 4th quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock valued at $60,000 after buying an additional 2,500 shares during the period. ProShare Advisors LLC lifted its holdings in shares of SELLAS Life Sciences Group by 31.5% in the 4th quarter. ProShare Advisors LLC now owns 22,638 shares of the company’s stock valued at $85,000 after buying an additional 5,417 shares during the period. CWM LLC lifted its holdings in shares of SELLAS Life Sciences Group by 124.7% in the 4th quarter. CWM LLC now owns 11,782 shares of the company’s stock valued at $44,000 after buying an additional 6,538 shares during the period. Larson Financial Group LLC acquired a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at about $26,000. Finally, Bank of America Corp DE lifted its holdings in shares of SELLAS Life Sciences Group by 21.9% in the 3rd quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock valued at $68,000 after buying an additional 7,571 shares during the period. Hedge funds and other institutional investors own 17.38% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group boosted their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Up 18.2%

Shares of SLS stock opened at $8.97 on Thursday. The stock has a market cap of $1.67 billion, a PE ratio of -39.00 and a beta of 2.24. The business has a 50-day simple moving average of $5.20 and a 200-day simple moving average of $3.87. SELLAS Life Sciences Group, Inc. has a 52-week low of $1.39 and a 52-week high of $9.10.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.